Jae Seung Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7999555/publications.pdf

Version: 2024-02-01

204	5,251	87888 38	123424 61
papers	citations	h-index	g-index

213	213	213	6965
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A New Class of SN2 Reactions Catalyzed by Protic Solvents:Â Facile Fluorination for Isotopic Labeling of Diagnostic Molecules. Journal of the American Chemical Society, 2006, 128, 16394-16397.	13.7	296
2	Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy. Journal of Nuclear Medicine, 2012, 53, 399-406.	5.0	227
3	[18F]3â€²-deoxy-3â€²-fluorothymidine PET for the diagnosis and grading of brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 653-659.	6.4	170
4	Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Annals of Neurology, 2013, 73, 584-593.	5.3	146
5	Utility of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncology, 2007, 43, 887-893.	1.5	125
6	Utility of combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncology, 2009, 45, 218-224.	1.5	112
7	Prediction of prognosis using standardized uptake value of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiotherapy and Oncology, 2008, 87, 211-216.	0.6	97
8	Synergistic Effects of Ischemia and Î²-Amyloid Burden on Cognitive Decline in Patients With Subcortical Vascular Mild Cognitive Impairment. JAMA Psychiatry, 2014, 71, 412.	11.0	90
9	¹⁸F Fluorodeoxyglucose PET/CT in Head and Neck Squamous Cell Carcinoma with Negative Neck Palpation Findings: A Prospective Study. Radiology, 2014, 271, 153-161.	7.3	83
10	Use of 18F-FDG PET for Primary Treatment Strategy in Patients with Squamous Cell Carcinoma of the Oropharynx. Journal of Nuclear Medicine, 2007, 48, 752-757.	5.0	80
11	Detection of Occult Primary Tumors in Patients with Cervical Metastases of Unknown Primary Tumors: Comparison of¹⁸F FDG PET/CT with Contrast-enhanced CT or CT/MR Imagingâ€"Prospective Study. Radiology, 2015, 274, 764-771.	7.3	80
12	Clinical effect of white matter network disruption related to amyloid and small vessel disease. Neurology, 2015, 85, 63-70.	1.1	79
13	Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2018, 51, 43-48.	2.2	79
14	Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology, 2014, 82, 1597-1604.	1.1	78
15	Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis Measured by ¹⁸F-FDG PET/CT in Salivary Gland Carcinomas. Journal of Nuclear Medicine, 2013, 54, 1032-1038.	5.0	70
16	Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiology of Aging, 2014, 35, 254-260.	3.1	70
17	Prognostic Value of Tumor ¹⁸F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck. Journal of Nuclear Medicine, 2008, 49, 1783-1789.	5.0	68
18	Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. Journal of Nuclear Medicine, 2007, 48, 240-6.	5.0	66

#	Article	IF	Citations
19	Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimer's and Dementia, 2015, 11, 494.	0.8	61
20	One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nuclear Medicine and Biology, 2007, 34, 345-351.	0.6	58
21	Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging. NeuroImage, 2019, 186, 690-702.	4.2	58
22	Changes in glucose metabolism and metabolites during the epileptogenic process in the lithiumâ€pilocarpine model of epilepsy. Epilepsia, 2012, 53, 860-869.	5.1	57
23	Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. Nuclear Medicine and Molecular Imaging, 2013, 47, 44-51.	1.0	57
24	Amyloid Deposition in Early Onset versus Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 813-821.	2.6	57
25	Total MRI Small Vessel Disease Burden Correlates with Cognitive Performance, Cortical Atrophy, and Network Measures in a Memory Clinic Population. Journal of Alzheimer's Disease, 2018, 63, 1485-1497.	2.6	55
26	Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. European Journal of Cancer, 2019, 116, 98-106.	2.8	54
27	The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiology of Aging, 2013, 34, 1913-1920.	3.1	53
28	Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by 18F-FDG PET/CT in squamous cell carcinoma of the oral cavity. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 452-461.	6.4	53
29	Is normosmic Parkinson disease a unique clinical phenotype?. Neurology, 2015, 85, 1270-1275.	1.1	53
30	Relative impact of amyloid-Î², lacunes, and downstream imaging markers on cognitive trajectories. Brain, 2016, 139, 2516-2527.	7.6	51
31	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimerâ€™s disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	6.4	51
32	Is <scp>D</scp>ominantâ€<scp>S</scp>ide <scp>O</scp>nset <scp>A</scp>ssociated <scp>W</scp>ith a <scp>B</scp>etter <scp>M</scp>otor <scp>C</scp>ompensation in <scp>P</scp>arkinson's <scp>D</scp>isease?. Movement Disorders, 2015, 30, 1921-1925.	3.9	47
33	Cognitive deficits of pure subcortical vascular dementia vs Alzheimer disease. Neurology, 2013, 80, 569-573.	1.1	44
34	Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology, 2015, 85, 1687-1693.	1.1	44
35	Intratumor Textural Heterogeneity on Pretreatment 18F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer. Annals of Surgical Oncology, 2015, 22, 2746-2754.	1.5	43
36	Distinctive Resting State Network Disruptions Among Alzheimerâ€™s Disease, Subcortical Vascular Dementia, and Mixed Dementia Patients. Journal of Alzheimer's Disease, 2016, 50, 709-718.	2.6	41

#	Article	IF	Citations
37	18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer. European Journal of Cancer, 2017, 72, 62-70.	2.8	41
38	¹⁸F FDG PET/CT versus CT/MR Imaging and the Prognostic Value of Contralateral Neck Metastases in Patients with Head and Neck Squamous Cell Carcinoma. Radiology, 2016, 279, 481-491.	7.3	40
39	Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. Oral Oncology, 2019, 95, 95-99.	1.5	40
40	Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography for detecting contralateral neck metastases in patients with head and neck squamous cell carcinoma. Oral Oncology, 2011, 47, 376-380.	1.5	39
41	Evaluation of 18F-FDG PET/CT and CT/MRI with Histopathologic Correlation in Patients Undergoing Salvage Surgery for Head and Neck Squamous Cell Carcinoma. Annals of Surgical Oncology, 2011, 18, 2579-2584.	1.5	39
42	Utility of 18F-FDG PET/CT for Detecting Neck Metastasis in Patients with Salivary Gland Carcinomas: Preoperative Planning for Necessity and Extent of Neck Dissection. Annals of Surgical Oncology, 2013, 20, 899-905.	1.5	39
43	Impact of 18F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study. European Journal of Cancer, 2016, 63, 88-96.	2.8	39
44	Cortical Thinning in Subcortical Vascular Dementia with Negative 11C-PiB PET. Journal of Alzheimer's Disease, 2012, 31, 315-323.	2.6	37
45	Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiology of Aging, 2015, 36, 485-491.	3.1	37
46	The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 332-341.	6.4	37
47	Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease. Neurobiology of Aging, 2016, 38, 197-204.	3.1	36
48	The usefulness of hepatobiliary scintigraphy in the diagnosis of complications after adult-to-adult living donor liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 473-479.	6.4	35
49	Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1376-1381.	2.2	35
50	White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers. Journal of Alzheimer's Disease, 2014, 40, 877-886.	2.6	34
51	Prognostic significance of standardized uptake value and metabolic tumour volume on 18F-FDG PET/CT in oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1353-1361.	6.4	34
52	The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinsonâ€™s disease: Correlation with 18F-flurodeoxyglucose positron-emission tomography. Neuroscience Letters, 2015, 584, 296-301.	2.1	34
53	Different loss of dopamine transporter according to subtype of multiple system atrophy. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 517-525.	6.4	34
54	Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinsonâ€™s disease: a detailed PET analysis of 12 striatal subregions. Neurological Sciences, 2019, 40, 311-317.	1.9	33

#	Article	IF	Citations
55	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study. Scientific Reports, 2017, 7, 1910.	3.3	32
56	Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clinical Nuclear Medicine, 2017, 42, e80-e87.	1.3	31
57	Dopaminergic modulation of restingâ€state functional connectivity in de novo patients with Parkinson's disease. Human Brain Mapping, 2014, 35, 5431-5441.	3.6	30
58	Ictal Hyperperfusion Patterns in Relation to Ictal Scalp EEG Patterns in Patients with Unilateral Hippocampal Sclerosis: A SPECT Study. Epilepsia, 2007, 48, 270-277.	5.1	29
59	Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. NeuroReport, 2014, 25, 1198-1202.	1.2	29
60	Effects of Amyloid and Small Vessel Disease on White Matter Network Disruption. Journal of Alzheimer's Disease, 2015, 44, 963-975.	2.6	29
61	Synergistic effects of longitudinal amyloid and vascular changes on lobar microbleeds. Neurology, 2016, 87, 1575-1582.	1.1	28
62	Amide proton transfer imaging seems to provide higher diagnostic performance in post-treatment high-grade gliomas than methionine positron emission tomography. European Radiology, 2018, 28, 3285-3295.	4.5	27
63	White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 105-109.	2.2	27
64	3â€²-Deoxy-3â€²-18F-Fluorothymidine PET for the Early Prediction of Response to Leucovorin, 5-Fluorouracil, and Oxaliplatin Therapy in Patients with Metastatic Colorectal Cancer. Journal of Nuclear Medicine, 2013, 54, 1209-1216.	5.0	26
65	Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, 118-125.	0.8	25
66	Laryngeal edema after radiotherapy in patients with squamous cell carcinomas of the larynx and hypopharynx. Oral Oncology, 2012, 48, 853-858.	1.5	25
67	18F-FDG PET/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas. Clinical Nuclear Medicine, 2017, 42, e149-e156.	1.3	25
68	Premorbid exercise engagement and motor reserve in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 34, 49-53.	2.2	25
69	Chest radiography or chest CT plus head and neck CT versus 18F-FDG PET/CT for detection of distant metastasis and synchronous cancer in patients with head and neck cancer. Oral Oncology, 2019, 88, 109-114.	1.5	25
70	Diagnostic Value of Neck Node Status Using ¹⁸F-FDG PET for Salivary Duct Carcinoma of the Major Salivary Glands. Journal of Nuclear Medicine, 2012, 53, 881-886.	5.0	24
71	Subregional Pattern of Striatal Dopamine Transporter Loss on ¹⁸F FP-CIT Positron Emission Tomography in Patients With Pure Akinesia With Gait Freezing. JAMA Neurology, 2016, 73, 1477.	9.0	24
72	Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 33-40.	6.4	24

#	Article	IF	Citations
73	Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 423-431.	6.4	24
74	Areas of white matter hyperintensities and motor symptoms of Parkinson disease. Neurology, 2020, 95, e291-e298.	1.1	24
75	Relationship between hypometabolic patterns and ictal scalp EEG patterns in patients with unilateral hippocampal sclerosis: An FDGâ€“PET study. Epilepsy Research, 2009, 84, 187-193.	1.6	23
76	Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging. PLoS ONE, 2016, 11, e0157410.	2.5	23
77	Lymph node standardized uptake values at pre-treatment ¹⁸F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma. British Journal of Radiology, 2017, 90, 20160239.	2.2	23
78	¹⁸F-FDG PET/CTvs. human papillomavirus, p16 and Epstein-Barr virus detection in cervical metastatic lymph nodes for identifying primary tumors. International Journal of Cancer, 2017, 140, 1405-1412.	5.1	23
79	The presence of depression in de novo Parkinsonâ€™s disease reflects poor motor compensation. PLoS ONE, 2018, 13, e0203303.	2.5	23
80	Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas. Journal of Surgical Oncology, 2014, 110, 869-875.	1.7	22
81	18F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic Epithelial Tumors. Nuclear Medicine and Molecular Imaging, 2010, 44, 177-184.	1.0	21
82	Effects of APOE É›4 on brain amyloid, lacunar infarcts, and white matter lesions: aÂstudy among patients with subcortical vascular cognitive impairment. Neurobiology of Aging, 2013, 34, 2482-2487.	3.1	20
83	The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1585-1595.	6.4	20
84	Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 54-59.	2.2	20
85	18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 237-244.	2.5	20
86	New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: a 1.5-year production report. Nuclear Medicine and Biology, 2011, 38, 593-597.	0.6	19
87	Diagnostic Usefulness of 3â€™-Deoxy-3â€™-[18F]Fluorothymidine Positron Emission Tomography in Recurrent Brain Tumor. Journal of Computer Assisted Tomography, 2011, 35, 679-684.	0.9	19
88	Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative 18 F-FDG PET/CT measurements. Oral Oncology, 2018, 77, 98-104.	1.5	19
89	Effects of dopaminergic depletion and brain atrophy on neuropsychiatric symptoms in de novo Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 197-204.	1.9	19
90	The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease. Clinical Nuclear Medicine, 2018, 43, 787-792.	1.3	19

#	Article	IF	Citations
91	Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 357-366.	6.4	19
92	Comparison of Amyloid Î² and Tau Spread Models in Alzheimerâ€™s Disease. Cerebral Cortex, 2019, 29, 4291-4302.	2.9	19
93	Early- vs late-onset subcortical vascular cognitive impairment. Neurology, 2016, 86, 527-534.	1.1	18
94	Risk Estimation for Biliary Atresia in Patients with Neonatal Cholestasis: Development and Validation of a Risk Score. Radiology, 2018, 288, 262-269.	7.3	18
95	Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism. Journal of the Neurological Sciences, 2011, 301, 12-13.	0.6	17
96	Comparison between the radionuclide salivagram and videofluoroscopic swallowing study methods for evaluating patients with aspiration pneumonia. Annals of Nuclear Medicine, 2013, 27, 247-252.	2.2	16
97	Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off. Parkinsonism and Related Disorders, 2018, 53, 96-100.	2.2	16
98	Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. Clinical Nuclear Medicine, 2020, 45, 841-847.	1.3	16
99	Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. Neurological Sciences, 2015, 36, 269-274.	1.9	15
100	Synthesis and evaluation of 6-(3-[18F]fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging AÎ² plaques. Bioorganic and Medicinal Chemistry, 2016, 24, 2043-2052.	3.0	15
101	Does smoking impact dopamine neuronal loss in de novo Parkinson disease?. Annals of Neurology, 2017, 82, 850-854.	5.3	15
102	The impact of education on cortical thickness in amyloid-negative subcortical vascular dementia: cognitive reserve hypothesis. Alzheimer's Research and Therapy, 2018, 10, 103.	6.2	15
103	PET/CT Fusion Viewing Software for Use with Picture Archiving and Communication Systems. Journal of Digital Imaging, 2010, 23, 732-743.	2.9	14
104	Preoperative Contrast-Enhanced CT Versus 18F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma. Annals of Surgical Oncology, 2015, 22, 1020-1027.	1.5	14
105	Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 169-174.	1.9	14
106	Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Scientific Reports, 2021, 11, 14992.	3.3	14
107	Use of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Rare Head and Neck Cancers. Clinical and Experimental Otorhinolaryngology, 2008, 1, 103.	2.1	14
108	The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nuclear Medicine and Molecular Imaging, 2014, 48, 287-294.	1.0	13

#	Article	IF	Citations
109	Striatofrontal Deafferentiation in MSA-P: Evaluation with [18F]FDG Brain PET. PLoS ONE, 2017, 12, e0169928.	2.5	13
110	Association of striatal dopaminergic neuronal integrity with cognitive dysfunction and cerebral cortical metabolism in Parkinsonâ€™s disease with mild cognitive impairment. Nuclear Medicine Communications, 2019, 40, 1216-1223.	1.1	13
111	The impact of skeletal muscle depletion on older adult patients with head and neck cancer undergoing primary surgery. Journal of Geriatric Oncology, 2021, 12, 128-133.	1.0	13
112	Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. British Journal of Surgery, 2021, 109, 61-70.	0.3	13
113	Different subregional metabolism patterns in patients with cerebellar ataxia by 18F-fluorodeoxyglucose positron emission tomography. PLoS ONE, 2017, 12, e0173275.	2.5	13
114	18F-Fluorodeoxyglucose Positron-Emission Tomography Findings with Anti-N-Methyl-D-Aspartate Receptor Encephalitis that Showed Variable Degrees of Catatonia: Three Cases Report. Journal of Epilepsy Research, 2014, 4, 69-73.	0.4	13
115	Comparison of Videofluoroscopic Swallowing Study and Radionuclide Salivagram for Aspiration Pneumonia in Children With Swallowing Difficulty. Annals of Rehabilitation Medicine, 2018, 42, 52.	1.6	13
116	Effects of Cognitive Reserve in Alzheimerâ€™s Disease and Cognitively Unimpaired Individuals. Frontiers in Aging Neuroscience, 2021, 13, 784054.	3.4	13
117	Uneven age effects of [18F]FP-CIT binding in the striatum of Parkinsonâ€™s disease. Annals of Nuclear Medicine, 2014, 28, 874-879.	2.2	12
118	The Role of Cerebrovascular Disease inÂAmyloid Deposition. Journal of Alzheimer's Disease, 2016, 54, 1015-1026.	2.6	12
119	Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinsonâ€™s Disease. Nuclear Medicine and Molecular Imaging, 2017, 51, 304-313.	1.0	12
120	Detection of distant metastasis and prognostic prediction of recurrent salivary gland carcinomas using ¹⁸Fâ€FDG PET/CT. Oral Diseases, 2018, 24, 940-947.	3.0	12
121	Higher sympathetic activity as a risk factor for skeletal deterioration in pheochromocytoma. Bone, 2018, 116, 1-7.	2.9	12
122	PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 1821-1831.	7.0	12
123	Clinical values for abnormal 18F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma. European Journal of Radiology, 2014, 83, 1455-1460.	2.6	11
124	Imaging Atherosclerosis in the Carotid Arteries with F-18-Fluoro-2-deoxy-D-glucose Positron Emission Tomography: Effect of Imaging Time after Injection on Quantitative Measurement. Nuclear Medicine and Molecular Imaging, 2010, 44, 261-266.	1.0	10
125	Regional amyloid burden and lacune in pure subcortical vascular cognitive impairment. Neurobiology of Aging, 2017, 55, 20-26.	3.1	10
126	Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma. Head and Neck, 2019, 41, 1846-1853.	2.0	10

#	Article	IF	Citations
127	Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 10343.	3.3	10
128	The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloidâ€negative amnestic mild cognitive impairment. European Journal of Neurology, 2021, 28, 1520-1527.	3.3	9
129	Hepatobiliary scintigraphy in the assessment of biliary obstruction after hepatic resection with biliary-enteric anastomosis. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 170-175.	6.4	8
130	Effect of Animal Condition and Fluvoxamine on the Result of [18F]N-3-Fluoropropyl-2Î²-carbomethoxy-3Î²-(4-iodophenyl) Nortropane ([18F]FP-CIT) PET Study in Mice. Nuclear Medicine and Molecular Imaging, 2012, 46, 27-33.	1.0	8
131	Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome. Neurological Sciences, 2013, 34, 875-881.	1.9	8
132	Individual Subject Classification of Mixed Dementia from Pure Subcortical Vascular Dementia Based on Subcortical Shape Analysis. PLoS ONE, 2013, 8, e75602.	2.5	8
133	¹⁸Fâ€fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 652-655.	2.0	8
134	Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2485-2493.	2.5	8
135	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. BMC Neurology, 2019, 19, 211.	1.8	8
136	3â€²-Deoxy-3â€™-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1713-1722.	6.4	8
137	Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease. Clinical Nuclear Medicine, 2019, 44, 855-859.	1.3	8
138	Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. Targeted Oncology, 2019, 14, 689-697.	3.6	7
139	Neural and dopaminergic correlates of fatigue in Parkinsonâ€™s disease. Journal of Neural Transmission, 2020, 127, 301-309.	2.8	7
140	Post-treatment 18F-FDG PET/CT for predicting survival and recurrence in patients with advanced-stage head and neck cancer undergoing curative surgery. Oral Oncology, 2020, 107, 104750.	1.5	7
141	Preserved Hippocampal Glucose Metabolism on ¹⁸F-FDG PET after Transplantation of Human Umbilical Cord Blood-derived Mesenchymal Stem Cells in Chronic Epileptic Rats. Journal of Korean Medical Science, 2015, 30, 1232.	2.5	6
142	Clinical significance of visually equivocal amyloid PET findings from the Alzheimerâ€™s Disease Neuroimaging Initiative cohort. NeuroReport, 2018, 29, 553-558.	1.2	6
143	Clinical significance of the post-radiotherapy ¹⁸F-fludeoxyglucose positron emission tomography response in nasopharyngeal carcinoma. British Journal of Radiology, 2019, 92, 20180045.	2.2	6
144	The Local and Systemic Interactions Between Muscle and Bone in Postmenopausal Korean Women. Calcified Tissue International, 2019, 105, 373-382.	3.1	6

#	Article	IF	Citations
145	Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimerâ€™s disease differ according to disease severity and amyloid positivity. PLoS ONE, 2019, 14, e0226265.	2.5	6
146	Testâ€“retest reproducibility of dopamine transporter density measured with [18F]FP-CIT PET in patients with essential tremor and Parkinsonâ€™s disease. Annals of Nuclear Medicine, 2021, 35, 299-306.	2.2	6
147	Associations of Circulating Levels of Sphingosine 1-Phosphate with the Trabecular Bone Score and Bone Mineral Density in Postmenopausal Women. Journal of Clinical Densitometry, 2021, 24, 414-421.	1.2	6
148	Clinical Implications of Amyloid-Beta Accumulation in Occipital Lobes in Alzheimerâ€™s Continuum. Brain Sciences, 2021, 11, 1232.	2.3	6
149	Asymmetry of cerebral glucose metabolism in very low-birth-weight infants without structural abnormalities. PLoS ONE, 2017, 12, e0186976.	2.5	6
150	Unified Deep Learning-Based Mouse Brain MR Segmentation: Template-Based Individual Brain Positron Emission Tomography Volumes-of-Interest Generation Without Spatial Normalization in Mouse Alzheimer Model. Frontiers in Aging Neuroscience, 2022, 14, 807903.	3.4	6
151	Prognostic value of ¹⁸Fâ€FDG PET/CT parameters in patients who undergo salvage treatments for recurrent squamous cell carcinoma of the larynx and hypopharynx. Journal of Surgical Oncology, 2018, 118, 644-650.	1.7	5
152	Parkinson Disease-Related Pattern of Glucose Metabolism Associated With the Potential for Motor Improvement After Deep Brain Stimulation. Neurosurgery, 2019, 86, 492-499.	1.1	5
153	Distinct clinical features of predominant pre-synaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy. Journal of the Neurological Sciences, 2019, 402, 100-106.	0.6	5
154	Prediction of cervical metastasis and survival in cN0 oral cavity cancer using tumour 18F-FDG PET/CT functional parameters. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3341-3348.	2.5	5
155	¹⁸F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in Î²-Amyloid-Negative Amnestic Mild Cognitive Impairment. Yonsei Medical Journal, 2022, 63, 259.	2.2	5
156	Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver. Annals of Surgical Treatment and Research, 2022, 102, 335.	1.0	5
157	Ictal singing due to right mesial temporal lobe epilepsy involving a bihemispheric network. Epilepsy & Behavior Case Reports, 2013, 1, 85-88.	1.5	4
158	Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinsonâ€™s Disease?. CNS Drugs, 2018, 32, 971-979.	5.9	4
159	False-negative Hepatobiliary Scintigraphy for Biliary Atresia. Nuclear Medicine and Molecular Imaging, 2019, 53, 356-360.	1.0	4
160	Clinical utility of ¹⁸F-FDG PET/CT for patients with recurrent head and neck squamous cell carcinoma. Acta Oto-Laryngologica, 2019, 139, 810-815.	0.9	4
161	Tau Imaging: New Era of Neuroimaging for Alzheimerâ€™s Disease. Nuclear Medicine and Molecular Imaging, 2020, 54, 161-162.	1.0	4
162	Genetic alterations associated with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in head and neck squamous cell carcinoma. Translational Oncology, 2021, 14, 100988.	3.7	4

#	Article	IF	Citations
163	FDG-PET patterns associated with ideomotor apraxia and imitation apraxia in patients with corticobasal syndrome. Parkinsonism and Related Disorders, 2021, 88, 96-101.	2.2	4
164	Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy. Journal of Movement Disorders, 2009, 2, 22-28.	1.3	4
165	Molecular Imaging in Neurodegenerative Diseases. Journal of the Korean Medical Association, 2009, 52, 151.	0.3	3
166	Clinical features and nigrostriatal dysfunction in patients with combined postural and resting tremors. Parkinsonism and Related Disorders, 2013, 19, 1118-1122.	2.2	3
167	Immune microenvironment of the gene signature reflecting the standardised uptake value on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in head and neck squamous cell carcinoma. Annals of Nuclear Medicine, 2021, 35, 65-75.	2.2	3
168	Role of White Matter Abnormalities in the Relationship Between Microbleed Burden and Cognitive Impairment in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2022, 86, 667-678.	2.6	3
169	[¹⁸F]THK-5351 PET Patterns in Patients With Alzheimerâ€™s Disease and Negative Amyloid PET		

#	Article	IF	Citations
181	P2-208: INCIDENT CEREBRAL MICROBLEEDS IN SUBJECTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: LONGITUDINAL STUDY. , 2014, 10, P548-P549.		0
182	O5-01-01: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P286-P287.		0
183	P3-217: BLINDED VISUAL EVALUATION AND QUANTITATIVE SUVR THRESHOLD CLASSIFICATION OF [18F]FLUTEMETAMOL PET IMAGES IN JAPANESE SUBJECTS. , 2014, 10, P710-P710.		0
184	IC-P-186: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P103-P104.		0
185	Software development for ACR-approved phantom-based nuclear medicine tomographic image quality control with cross-platform compatibility. Journal of the Korean Physical Society, 2015, 67, 323-328.	0.7	0
186	Optimized statistical parametric mapping for partial-volume-corrected amyloid positron emission tomography in patients with Alzheimerâ€™s disease and Lewy body dementia. Journal of the Korean Physical Society, 2017, 70, 454-459.	0.7	0
187	[P1â€“129]: PREDICTION MODEL OF TAU PROPAGATION IN AD SPECTRUM USING FUNCTIONAL NETWORK. Alzheimer's and Dementia, 2017, 13, P291.	0.8	0
188	[P2â€“361]: SURFACEâ€BASED ANALYSIS OF SUBâ€CORTICAL STRUCTURES IN TAU AND AMYLOID PET IMAGING: AN ALZHEIMER'S DISEASE STUDY. Alzheimer's and Dementia, 2017, 13, P762.	0.8	0
189	[P2â€“406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING ¹⁸Fâ€THK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.8	0
190	[P2â€“424]: PROTECTIVE EFFECTS OF EDUCATION ON THKâ€5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NONâ€ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	0.8	0
191	[P3â€“319]: MILD COGNITIVE IMPAIRMENT CLASSIFICATION USING DEEP LEARNING. Alzheimer's and Dementia, 2017, 13, P1070.	0.8	0
192	[P3â€“330]: COMPARISON OF QUANTITATIVE TAU DEPOSITION ON THKâ€5351 PET IMAGING AND HIPPOCAMPAL VOLUME IN DIAGNOSIS OF ALZHEIMER's DISEASE SPECTRUM. Alzheimer's and Dementia, 2017, 13, P1077.	0.8	0
193	[P3â€“337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.8	0
194	[P4â€“046]: PARTIAL VOLUME SUSCEPTIBILITY OF TAU PET: REGIONWISE ASSESSMENT AND COMPARISON WITH AMYLOID PET. Alzheimer's and Dementia, 2017, 13, P1274.	0.8	0
195	[P4â€“253]: QUANTITATIVE ANALYSIS AND CORRELATION WITH COGNITIVE FUNCTION OF Fâ€18 THKâ€5351 PET IN SUBJECTIVE MEMORY IMPAIRMENT, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1377.	0.8	0
196	[P1â€“454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€5351 UPTAKES IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.8	0
197	[O1â€“08â€“01]: PATTERNS OF REGIONAL TAU ACCUMULATION INDICATIVE OF THREE DIFFERENT TYPES OF ALZHEIMER'S DISEASE (AD): THK5351â€PETâ€BASED REPLICATION OF PATHOLOGYâ€BASED AD CLASSIFICATION. Alzheimer's and Dementia, 2017, 13, P206.	0.8	0
198	P2â€359: RELATION NETWORKS OF NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECTRUM: TAU, AMYLOID, AND CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P827.	0.8	0

#	Article	IF	Citations
199	P1â€396: COGNITION AND NEUROFIBRILLARY DEGENERATION IN PATIENTS WITH AMYLOIDâ€NEGATIVE MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P454.	0.8	0
200	O1â€14â€03: NATURAL HISTORY OF SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: AN 8.5â€YEAR LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P258.	0.8	0
201	P3â€089: DATAâ€DRIVEN PATHOLOGICAL POSITIVITY OF ALZHEIMER DISEASE: AN EXPLORATORY STUDY OF DYNAMIC BIOMARKER CAUSALITY. Alzheimer's and Dementia, 2018, 14, P1099.	0.8	0
202	P3â€433: NEURAL SUBSTRATES OF COGNITIVE RESERVE IN THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P1277.	0.8	0
203	60 Years of Achievements by KSNM in Neuroimaging Research. Nuclear Medicine and Molecular Imaging, 2022, 56, 3-16.	1.0	0
204	Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S297-S297.	0.1	0